Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

Autor: Wortman, B.G., Creutzberg, C.L., Putter, H., Jurgenliemk-Schulz, I.M., Jobsen, J.J., Lutgens, L.C.H.W., Steen-Banasik, E.M. van der, Mens, J.W.M., Slot, A., Kroese, M.C.S., Triest, B. van, Nijman, H.W., Stelloo, E., Bosse, T., Boer, S.M. de, Putten, W.L.J. van, Smit, V.T.H.B.M., Nout, R.A., PORTEC Study Grp

Publikováno v: British Journal of Cancer, 119(9), 1067-1074
British Journal of Cancer
British Journal of Cancer, 119(9), 1067-1074. Nature Publishing Group

BACKGROUND: PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal brachytherapy (VBT). We evaluated long-term outcomes combined with the results

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4323ee51d7efa4e63c525cf8f65e972
https://hdl.handle.net/1887/86376

Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression

Autor: Triest, B. Van, Pinedo, H. M., Telleman, F., Wilt, C. L. Van der, Jansen, G., Peters, G. J.

Publikováno v: Biochemical Pharmacology; 1997, Vol. 53 Issue: 12 p1855-1866, 12p

1845PSafety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials.

Autor: Mau-Sorensen, M¹ (AUTHOR), Bussel, M van² (AUTHOR), Kuipers, M³ (AUTHOR), Nielsen, D L⁴ (AUTHOR), Verheul, H M⁵ (AUTHOR), Aftimos, P⁶ (AUTHOR), Jonge, M J A de⁷ (AUTHOR), Triest, B van² (AUTHOR), Falkenius, J⁸ (AUTHOR), Debus, J⁹ (AUTHOR)

Publikováno v: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.